| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| CRLCharles River Laboratories International, Inc. | 11B | 223.47 | 1117.35 | -1.92% | -2.07% | -2.42% | 4.56% | 0.78 |
| SHCSotera Health Company | 5.5B | 19.35 | 120.94 | 4.88% | 4.82% | 10.07% | 0.82% | 5.81 |
| ISPCiSpecimen Inc. | 4.22M | 0.42 | -0.02 | -6.42% | -343.99% | -375.34% | 0.09 | |
| NOTVInotiv, Inc. | 19.59M | 0.57 | -0.27 | 4.54% | -13.38% | -50.45% | 3.01 | |
| ACRSAclaris Therapeutics, Inc. | 289.28M | 2.67 | -1.56 | -40.09% | -9% | -117.97% |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 4.39M | 4.3M | 8.18M | 11.14M | 10.4M | 9.93M | 9.29M |
| Revenue Growth % | - | -0.02% | 0.9% | 0.36% | -0.07% | -0.05% | -0.06% |
| Cost of Goods Sold | 2.36M | 2.13M | 3.59M | 5.25M | 4.76M | 4.82M | 5.3M |
| COGS % of Revenue | 0.54% | 0.5% | 0.44% | 0.47% | 0.46% | 0.49% | 0.57% |
| Gross Profit | 2.03M | 2.17M | 4.6M | 5.89M | 5.65M | 5.11M | 3.99M |
| Gross Margin % | 0.46% | 0.5% | 0.56% | 0.53% | 0.54% | 0.51% | 0.43% |
| Gross Profit Growth % | - | 0.07% | 1.12% | 0.28% | -0.04% | -0.1% | -0.22% |
| Operating Expenses | 5.39M | 6.05M | 7.01M | 11.81M | 15.83M | 16.28M | 16.72M |
| OpEx % of Revenue | 1.23% | 1.41% | 0.86% | 1.06% | 1.52% | 1.64% | 1.8% |
| Selling, General & Admin | 3.51M | 4.26M | 5.04M | 9.4M | 12.37M | 11.68M | 12.65M |
| SG&A % of Revenue | 0.8% | 0.99% | 0.62% | 0.84% | 1.19% | 1.18% | 1.36% |
| Research & Development | 1.21M | 993.33K | 1.47M | 1.84M | 2.66M | 3.57M | 3.53M |
| R&D % of Revenue | 0.28% | 0.23% | 0.18% | 0.17% | 0.26% | 0.36% | 0.38% |
| Other Operating Expenses | 41.73K | 792.78K | 497.18K | 573.91K | 801.13K | 1.03M | 537.89K |
| Operating Income | -3.36M | -3.88M | -2.41M | -5.93M | -10.19M | -11.17M | -12.73M |
| Operating Margin % | -0.76% | -0.9% | -0.29% | -0.53% | -0.98% | -1.13% | -1.37% |
| Operating Income Growth % | - | -0.16% | 0.38% | -1.46% | -0.72% | -0.1% | -0.14% |
| EBITDA | -2.89M | -3.25M | -1.59M | -4.92M | -8.98M | -9.1M | -12.78M |
| EBITDA Margin % | -0.66% | -0.75% | -0.19% | -0.44% | -0.86% | -0.92% | -1.38% |
| EBITDA Growth % | - | -0.12% | 0.51% | -2.1% | -0.82% | -0.01% | -0.4% |
| D&A (Non-Cash Add-back) | 469.17K | 634.97K | 819.69K | 1M | 1.21M | 2.07M | -56.47K |
| EBIT | -4.26M | -3.16M | -2.56M | -6.86M | -10.01M | -10.87M | -12.67M |
| Net Interest Income | -1.21M | -1.72M | -2.1M | -2.09M | -69.62K | 108.97K | -175.94K |
| Interest Income | 1.5K | 630 | 437 | 11.4K | 169.34K | 339.75K | 44.13K |
| Interest Expense | 1.21M | 1.72M | 2.1M | 2.1M | 238.96K | 230.78K | 220.07K |
| Other Income/Expense | -2.12M | -1M | -2.25M | -3.04M | -59.84K | 69.86K | 230.24K |
| Pretax Income | -5.47M | -4.88M | -4.65M | -8.96M | -10.25M | -11.1M | -12.5M |
| Pretax Margin % | -1.25% | -1.14% | -0.57% | -0.8% | -0.98% | -1.12% | -1.35% |
| Income Tax | -127K | -157K | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0.98% | 0.97% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -5.35M | -4.73M | -4.65M | -8.96M | -10.25M | -11.1M | -12.5M |
| Net Margin % | -1.22% | -1.1% | -0.57% | -0.8% | -0.98% | -1.12% | -1.35% |
| Net Income Growth % | - | 0.12% | 0.02% | -0.93% | -0.14% | -0.08% | -0.13% |
| Net Income (Continuing) | -5.35M | -4.73M | -4.65M | -8.96M | -10.25M | -11.1M | -12.5M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -114.11 | -100.99 | -144.38 | -24.51 | -20.44 | -24.55 | -17.58 |
| EPS Growth % | - | 0.11% | -0.43% | 0.83% | 0.17% | -0.2% | 0.28% |
| EPS (Basic) | -114.11 | -100.99 | -144.38 | -24.51 | -20.47 | -1.23 | -17.58 |
| Diluted Shares Outstanding | 46.86K | 46.8K | 46.81K | 408.62K | 442.21K | 452.07K | 710.85K |
| Basic Shares Outstanding | 46.86K | 46.8K | 46.81K | 408.62K | 441.63K | 452.07K | 710.85K |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 2.3M | 1.58M | 3.47M | 32.95M | 19.68M | 8.24M | 3.59M |
| Cash & Short-Term Investments | 1.13M | 53.89K | 695.91K | 27.74M | 15.31M | 5.01M | 1.88M |
| Cash Only | 1.13M | 53.89K | 695.91K | 27.74M | 15.31M | 2.34M | 1.88M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 2.66M | 0 |
| Accounts Receivable | 1.03M | 1.39M | 2.36M | 4.88M | 3.93M | 2.94M | 1.44M |
| Days Sales Outstanding | 85.2 | 118.26 | 105.19 | 160.04 | 137.75 | 108.12 | 56.75 |
| Inventory | 47.29K | 54.91K | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 7.31 | 9.42 | - | - | - | - | - |
| Other Current Assets | 0 | 79.23K | 0 | 0 | 140.87K | 292.08K | 264.89K |
| Total Non-Current Assets | 1.74M | 2.63M | 2.74M | 2.77M | 4.94M | 7.58M | 5.76M |
| Property, Plant & Equipment | 149.1K | 119.92K | 75.59K | 32.78K | 410.54K | 321.64K | 421.54K |
| Fixed Asset Turnover | 29.48x | 35.84x | 108.27x | 339.69x | 25.34x | 30.87x | 22.04x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 1.44M | 2.31M | 2.63M | 2.71M | 4.5M | 7.23M | 5.33M |
| Long-Term Investments | 127K | 179.52K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 154.6K | 207.12K | 27.6K | 27.6K | 27.6K | 27.6K | 12.1K |
| Total Assets | 4.04M | 4.21M | 6.21M | 35.72M | 24.62M | 15.82M | 9.35M |
| Asset Turnover | 1.09x | 1.02x | 1.32x | 0.31x | 0.42x | 0.63x | 0.99x |
| Asset Growth % | - | 0.04% | 0.47% | 4.75% | -0.31% | -0.36% | -0.41% |
| Total Current Liabilities | 11.3M | 15.76M | 22.14M | 2.51M | 4.28M | 6.05M | 5.77M |
| Accounts Payable | 696.91K | 737.79K | 1.79M | 832.68K | 2.46M | 3.93M | 4.2M |
| Days Payables Outstanding | 107.67 | 126.55 | 182.47 | 57.9 | 188.68 | 297.24 | 288.93 |
| Short-Term Debt | 6.97M | 10.59M | 12.59M | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 864.91K | 1000K | 873.25K | 654.75K | 0 | 415.77K | 360.71K |
| Other Current Liabilities | 2.77M | 2.21M | 2.37M | 0 | 132.34K | 0 | 0 |
| Current Ratio | 0.20x | 0.10x | 0.16x | 13.15x | 4.60x | 1.36x | 0.62x |
| Quick Ratio | 0.20x | 0.10x | 0.16x | 13.15x | 4.60x | 1.36x | 0.62x |
| Cash Conversion Cycle | -15.17 | 1.12 | - | - | - | - | - |
| Total Non-Current Liabilities | 11.17M | 11.17M | 11.35M | 3.42M | 27.4K | 29.13K | 268.8K |
| Long-Term Debt | 0 | 0 | 178.9K | 3.42M | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 27.4K | 29.13K | 268.8K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 11.17M | 0 | 0 | 0 | 0 |
| Total Liabilities | 22.47M | 26.93M | 33.49M | 5.93M | 4.31M | 6.08M | 6.04M |
| Total Debt | 6.97M | 10.59M | 12.77M | 3.42M | 185.85K | 196.24K | 312.17K |
| Net Debt | 5.84M | 10.54M | 12.07M | -24.32M | -15.12M | -2.15M | -1.57M |
| Debt / Equity | - | - | - | 0.11x | 0.01x | 0.02x | 0.09x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | -2.76x | -2.25x | -1.15x | -2.82x | -42.63x | -48.40x | -57.84x |
| Total Equity | -18.42M | -22.72M | -27.28M | 29.79M | 20.31M | 9.74M | 3.31M |
| Equity Growth % | - | -0.23% | -0.2% | 2.09% | -0.32% | -0.52% | -0.66% |
| Book Value per Share | -393.19 | -485.39 | -582.73 | 72.91 | 45.93 | 21.55 | 4.66 |
| Total Shareholders' Equity | -18.42M | -22.72M | -27.28M | 29.79M | 20.31M | 9.74M | 3.31M |
| Common Stock | 537 | 537 | 94 | 873 | 892 | 908 | 170 |
| Retained Earnings | -19.75M | -24.41M | -29.06M | -38.02M | -48.27M | -59.36M | -71.86M |
| Treasury Stock | -172 | -172 | -172 | -172 | -172 | -172 | -172 |
| Accumulated OCI | -159.83K | 0 | 0 | 0 | 0 | 840 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -2.68M | -2.68M | -288.38K | -10.67M | -5.82M | -5.81M | -8.26M |
| Operating CF Margin % | -0.61% | -0.62% | -0.04% | -0.96% | -0.56% | -0.58% | -0.89% |
| Operating CF Growth % | - | 0% | 0.89% | -35.99% | 0.45% | 0% | -0.42% |
| Net Income | -5.35M | -4.73M | -4.65M | -8.96M | -10.25M | -11.1M | -12.5M |
| Depreciation & Amortization | 469.17K | 634.97K | 819.69K | 1M | 1.21M | 2.12M | 2.29M |
| Stock-Based Compensation | 113.92K | 360.38K | 92.87K | 622.06K | 678.61K | 459.67K | 249.68K |
| Deferred Taxes | 946K | -551K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 767.72K | 551.99K | 410.53K | 1.95M | 190.22K | 127.75K | 2.19M |
| Working Capital Changes | 368.49K | 1.05M | 3.04M | -5.28M | 2.35M | 2.59M | -502.67K |
| Change in Receivables | -393.19K | 192.25K | -894.47K | -2.68M | 709.18K | 820.61K | -397.4K |
| Change in Inventory | -12.66K | -7.62K | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 584.05K | 40.88K | 1.05M | -959.75K | 1.63M | 1.47M | 272.12K |
| Cash from Investing | -1.03M | -1.48M | -1.1M | -1.04M | -3.19M | -7.23M | 1.98M |
| Capital Expenditures | -1.03M | -1.48M | -426 | -2.55K | -215.5K | -19.48K | -31.55K |
| CapEx % of Revenue | 0.23% | 0.34% | 0% | 0% | 0.02% | 0% | 0% |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | -969.68K | -1.45M | -1.1M | -1.04M | -2.98M | -4.73M | -678.29K |
| Cash from Financing | 3.52M | 3.08M | 2.03M | 38.75M | -3.42M | 70.89K | 5.82M |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | 1.34M | 3.67K | 0 | -3.75M | 78.64K | 70.89K | 3.93M |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | -3.71M | -4.16M | -1.39M | -11.71M | -9.01M | -10.55M | -8.3M |
| FCF Margin % | -0.84% | -0.97% | -0.17% | -1.05% | -0.87% | -1.06% | -0.89% |
| FCF Growth % | - | -0.12% | 0.67% | -7.42% | 0.23% | -0.17% | 0.21% |
| FCF per Share | -79.12 | -88.78 | -29.72 | -28.65 | -20.37 | -23.34 | -11.67 |
| FCF Conversion (FCF/Net Income) | 0.50x | 0.57x | 0.06x | 1.19x | 0.57x | 0.52x | 0.66x |
| Interest Paid | 0 | 0 | 0 | 2.82M | 161.58K | 16K | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | -713.06% | -40.9% | -73.87% | -191.51% |
| Return on Invested Capital (ROIC) | - | - | - | - | -143.31% | -131.1% | -204.45% |
| Gross Margin | 46.24% | 50.5% | 56.19% | 52.86% | 54.27% | 51.45% | 42.93% |
| Net Margin | -121.67% | -109.97% | -56.84% | -80.48% | -98.5% | -111.8% | -134.51% |
| Debt / Equity | - | - | - | 0.11x | 0.01x | 0.02x | 0.09x |
| Interest Coverage | -2.76x | -2.25x | -1.15x | -2.82x | -42.63x | -48.40x | -57.84x |
| FCF Conversion | 0.50x | 0.57x | 0.06x | 1.19x | 0.57x | 0.52x | 0.66x |
| Revenue Growth | - | -2.2% | 90.4% | 36.06% | -6.58% | -4.56% | -6.42% |
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Product | - | - | - | 9.1M |
| Product Growth | - | - | - | - |
| Shipping and Handling | - | - | - | 186.16K |
| Shipping and Handling Growth | - | - | - | - |
| Specimens | 10.94M | 9.96M | 9.36M | - |
| Specimens Growth | - | -9.02% | -5.97% | - |
| Shipping and other | 191.05K | 445.72K | 566.46K | - |
| Shipping and other Growth | - | 133.30% | 27.09% | - |
iSpecimen Inc. (ISPC) reported $3.4M in revenue for fiscal year 2024. This represents a 24% decrease from $4.4M in 2018.
iSpecimen Inc. (ISPC) saw revenue decline by 6.4% over the past year.
iSpecimen Inc. (ISPC) reported a net loss of $11.5M for fiscal year 2024.
iSpecimen Inc. (ISPC) has a return on equity (ROE) of -191.5%. Negative ROE indicates the company is unprofitable.
iSpecimen Inc. (ISPC) had negative free cash flow of $6.8M in fiscal year 2024, likely due to heavy capital investments.